DCC-3009 Phase 1/2 Trial Targets Resistance Mutations in Advanced GIST Patients
核心洞察
DCC-3009 is a first-in-human pan-inhibitor designed to block both primary KIT (搜索) driver mutations and secondary resistance mutations in advanced gastrointestinal stromal tumors.
The phase 1/2 study aims to determine optimal dosing and safety profile for patients whose GIST (搜索) has progressed on multiple prior targeted therapies.
The trial requires intensive monitoring initially with frequent visits, gradually spreading out over time as researchers evaluate the drug's metabolism and side effects.
A new investigational therapy for advanced gastrointestinal stromal tumors (GIST (搜索)) is being evaluated in a first-in-human phase 1/2 clinical trial, offering potential hope for patients whose disease has progressed on multiple targeted therapies. DCC-3009, a pan-inhibitor specifically designed for advanced GIST, targets both primary driver mutations and resistance mutations in the KIT (搜索) gene.
Novel Mechanism Addresses Treatment Resistance
DCC-3009 represents a strategic approach to overcoming treatment resistance in GIST (搜索) patients. According to Dr. Suzanne George, senior physician and chief of the Division of Sarcoma at Dana-Farber Cancer Institute, the drug "blocks both the primary driver mutations in KIT (搜索), and we think it also blocks a wide range of secondary resistance mutations in KIT."
The mechanism addresses a critical challenge in GIST (搜索) treatment. "What we know is that the primary mechanism of resistance to earlier lines of therapy in GIST is developing new mutations, typically in that same driver we call KIT (搜索)," George explained. "Therefore, patients with resistant GIST usually have tumors with multiple mutations in this KIT gene, leading to its mutated protein."
DCC-3009 is designed to block these resistance mutations in addition to primary mutations, potentially performing better than currently available drugs for patients who have exhausted other treatment options.
Study Design and Patient Experience
The phase 1/2 study follows a traditional dose-escalation approach for first-in-human trials. "Patients are treated in small groups or cohorts at slowly escalating doses in order to identify the 'right dose' to move forward into further testing," George noted. The primary objectives include determining optimal dosing and evaluating the safety profile of the investigational agent.
Patient participation requires intensive monitoring, particularly during the initial treatment phase. "Patients need to come in for one or two doses even before they start their daily dose in order for the study team to begin to learn about how the drug is metabolized in the body and what the drug levels look like," George explained.
The visit schedule gradually becomes less demanding over time, transitioning from frequent initial visits to every couple of weeks, with further spacing anticipated as the study progresses. This intensive monitoring approach reflects the careful evaluation required for novel therapeutic agents.
Addressing Unmet Medical Needs
The trial specifically targets patients with advanced GIST (搜索) who have progressed on multiple prior targeted therapies, representing a population with significant unmet medical needs. The study was presented as a trial-in-progress at the 2025 Connective Tissue Oncology Society (搜索) (CTOS) Annual Meeting, highlighting its potential to fill gaps in current treatment options.
"We think it is an interesting study that could potentially fill an unmet need in patients with advanced GIST (搜索)," George stated, emphasizing the importance of making patients and providers aware of this potential treatment option.
Current Status and Accessibility
The study is currently enrolling patients but remains open at a limited number of centers, which is typical for early-phase trials. "Usually, it is just open at a more contained number of sites" due to the need for careful monitoring of side effects, tolerance, and drug efficacy, George explained.
No results are available yet from the study, as it is still in early development phases. However, the presentation at CTOS demonstrates the research community's commitment to advancing treatment options for patients with advanced GIST (搜索) who have limited therapeutic alternatives.
For patients interested in participation, connecting with actively participating sites is essential, as the study's availability is geographically limited during this early phase of development.